Organ fibrosis inhibited by blocking transforming growth factor-β signaling via peroxisome proliferator-activated receptor γ agonists

Hepatobiliary and Pancreatic Diseases International

Volumn 11, Issue 5, 2012, Pages 467-478

  Deng, Yi Lei ^a   Xiong, Xian Ze ^a   Cheng, Nan Sheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Fibrosis; PPAR gamma; Transforming growth factor

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; ALPHA SMOOTH MUSCLE ACTIN; BARDOXOLONE; CALPONIN; CIGLITAZONE; COLLAGEN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; KLOTHO PROTEIN; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; OSTEOGENIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SCLEROPROTEIN; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TROGLITAZONE; UVOMORULIN; VIMENTIN;

ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; FIBROSIS; HEART MUSCLE FIBROSIS; HUMAN; KELOID; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; MOLECULAR INTERACTION; MYOFIBROBLAST; NONHUMAN; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SKIN FIBROSIS;

EID: 84867762854     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(12)60210-0     Document Type: Review

References (109)

1. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
2. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect 1999;1:1349-1365.
3. Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol Med 2005;117:69-80.
4. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007;87:1077-1091.
5. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342: 1350-1358.
6. Gordon KJ, Blobe GC. Role of transforming growth factorbeta superfamily signaling pathways in human disease. Biochim Biophys Acta 2008;1782:197-228.
7. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-1428.
8. Zavadil J, Böttinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005;24:5764-5774.
9. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009;19:156-172.
10. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009;119:1438-1449.
11. Guarino M, Tosoni A, Nebuloni M. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition. Hum Pathol 2009;40:1365-1376.
12. Michalik L, Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol 1999;10:564-570.
13. Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000;448:121-138.
14. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, et al. Structure of the intact PPAR-gamma-RXRnuclear receptor complex on DNA. Nature 2008;456:350-356.
15. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005;51:85-94.
16. Costa V, Gallo MA, Letizia F, Aprile M, Casamassimi A, Ciccodicola A. PPARG: Gene Expression Regulation and Next-Generation Sequencing for Unsolved Issues. PPAR Res 2010;2010.
17. Chen WX, Li YM, Yu CH, Cai WM, Zheng M, Chen F. Quantitative analysis of transforming growth factor beta mRNA in patients with alcoholic liver disease. World J Gastroenterol 2002;8:379-381.
18. Gabriel A, Ziólkowski A, Radlowski P, Tomaszek K, Dziambor A. Hepatocyte steatosis in HCV patients promotes fibrosis by enhancing TGF-beta liver expression. Hepatol Res 2008;38: 141-146.
19. De Bleser PJ, Niki T, Rogiers V, Geerts A. Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J Hepatol 1997;26:886-893.
20. Zarin AA, Behmanesh M, Tavallaei M, Shohrati M, Ghanei M. Overexpression of transforming growth factor (TGF)-beta1 and TGF-beta3 genes in lung of toxic-inhaled patients. Exp Lung Res 2010;36:284-291.
21. Molina-Molina M, Lario S, Luburich P, Ramírez J, Carrión MT, Xaubet A. Quantifying plasma levels of transforming growth factor beta1 in idiopathic pulmonary fibrosis. Arch Bronconeumol 2006;42:380-383.
22. Wu W, Jiang XY, Zhang QL, Mo Y, Sun LZ, Chen SM. Expression and significance of TGF-beta1/Smad signaling pathway in children with IgA nephropathy. World J Pediatr 2009;5:211-215.
23. Lee SB, Kanasaki K, Kalluri R. Circulating TGF-beta1 as a reliable biomarker for chronic kidney disease progression in the African-American population. Kidney Int 2009;76:10-12.
24. Caletti MG, Balestracci A, Roy AH. Levels of urinary transforming growth factor beta-1 in children with D+ hemolytic uremic syndrome. Pediatr Nephrol 2010;25:1177-1180.
25. Koesters R, Kaissling B, Lehir M, Picard N, Theilig F, Gebhardt R, et al. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 2010;177:632-643.
26. Wang R, Ghahary A, Shen Q, Scott PG, Roy K, Tredget EE. Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. Wound Repair Regen 2000;8:128-137.
27. Chin GS, Liu W, Peled Z, Lee TY, Steinbrech DS, Hsu M, et al. Differential expression of transforming growth factorbeta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg 2001;108:423-429.
28. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A. Transforming growth factor-beta1 induces an epithelial-tomesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 2007;282:22089-22101.
29. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007;282:23337-23347.
30. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100:768-776.
31. Gu L, Zhu YJ, Yang X, Guo ZJ, Xu WB, Tian XL. Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation. Acta Pharmacol Sin 2007;28:382-391.
32. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, et al. PPARgamma agonists inhibit TGFbeta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005;288:L1146-1153.
33. Kim JH, Jang YS, Eom KS, Hwang YI, Kang HR, Jang SH, et al. Transforming growth factor beta1 induces epithelialto-mesenchymal transition of A549 cells. J Korean Med Sci 2007;22:898-904.
34. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGFbeta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005;6:56.
35. Mariasegaram M, Tesch GH, Verhardt S, Hurst L, Lan HY, Nikolic-Paterson DJ. Lefty antagonises TGF-beta1 induced epithelial-mesenchymal transition in tubular epithelial cells. Biochem Biophys Res Commun 2010;393:855-859.
36. Xu Y, Wan J, Jiang D, Wu X. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition in human renal proximal tubular epithelial cells. J Nephrol 2009;22: 403-410.
37. Friedman SL. Preface. Hepatic fibrosis: pathogenesis, diagnosis, and emerging therapies. Clin Liver Dis 2008;12: xiii-xiv.
38. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425-456.
39. Jiao J, Friedman SL, Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009;25:223-229.
40. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007;131:1728-1734.
41. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006;10:76-99.
42. Meindl-Beinker NM, Dooley S. Transforming growth factorbeta and hepatocyte transdifferentiation in liver fibrogenesis. J Gastroenterol Hepatol 2008;23:S122-127.
43. Choi SS, Diehl AM. Epithelial-to-mesenchymal transitions in the liver. Hepatology 2009;50:2007-2013.
44. Ikegami T, Zhang Y, Matsuzaki Y. Liver fibrosis: possible involvement of EMT. Cells Tissues Organs 2007;185:213-221.
45. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008;88:112-123.
46. Nitta T, Kim JS, Mohuczy D, Behrns KE. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 2008; 48:909-919.
47. Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, et al. Hepatocyte-specific Smad7 expression attenuates TGFbeta-mediated fibrogenesis and protects against liver damage. Gastroenterology 2008;135:642-659.
48. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009;136:1364-1370.
49. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007;132:1311-1321.
50. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009;2:103-121.
51. Sime PJ. The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis. J Investig Med 2008;56:534-538.
52. Koli K, Myllärniemi M, Keski-Oja J, Kinnula VL. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 2008;10:333-342.
53. Goodwin A, Jenkins G. Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans 2009;37:849-854.
54. Gharaee-Kermani M, Hu B, Phan SH, Gyetko MR. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast. Curr Med Chem 2009;16:1400-1417.
55. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010;6:643-656.
56. Cho MH. Renal fibrosis. Korean J Pediatr 2010;53:735-740.
57. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010;21:212-222.
58. García-Sánchez O, López-Hernández FJ, López-Novoa JM. An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int 2010;77:950-955.
59. Lee HS. Pathogenic role of TGF-β in the progression of podocyte diseases. Histol Histopathol 2011;26:107-116.
60. Böttinger EP. TGF-beta in renal injury and disease. Semin Nephrol 2007;27:309-320.
61. Schnaper HW, Jandeska S, Runyan CE, Hubchak SC, Basu RK, Curley JF, et al. TGF-beta signal transduction in chronic kidney disease. Front Biosci 2009;14:2448-2465.
62. Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999;56:1455-1467.
63. Hills CE, Squires PE. TGF-beta1-induced epithelial-tomesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 2010;31:68-74.
64. Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol 2007;25:26-32.
65. Shih B, Garside E, McGrouther DA, Bayat A. Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Repair Regen 2010;18:139-153.
66. Jagadeesan J, Bayat A. Transforming growth factor beta (TGFbeta) and keloid disease. Int J Surg 2007;5:278-285.
67. Klass BR, Grobbelaar AO, Rolfe KJ. Transforming growth factor beta1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance. Postgrad Med J 2009;85:9-14.
68. Bock O, Yu H, Zitron S, Bayat A, Ferguson MW, Mrowietz U. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars. Acta Derm Venereol 2005;85:216-220.
69. Bran GM, Goessler UR, Baftiri A, Hormann K, Riedel F, Sadick H. Effect of transforming growth factor-beta1 antisense oligonucleotides on matrix metalloproteinases and their inhibitors in keloid fibroblasts. Otolaryngol Head Neck Surg 2010;143:66-71.
70. Hsu YC, Chen MJ, Yu YM, Ko SY, Chang CC. Suppression of TGF-β1/SMAD pathway and extracellular matrix production in primary keloid fibroblasts by curcuminoids: its potential therapeutic use in the chemoprevention of keloid. Arch Dermatol Res 2010;302:717-724.
71. Zhang Z, Garron TM, Li XJ, Liu Y, Zhang X, Li YY, et al. Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns 2009;35:527-537.
72. Sandulache VC, Parekh A, Li-Korotky H, Dohar JE, Hebda PA. Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis. Wound Repair Regen 2007;15: 122-133.
73. Greene ME, Pitts J, McCarville MA, Wang XS, Newport JA, Edelstein C, et al. PPARgamma: observations in the hematopoietic system. Prostaglandins Other Lipid Mediat 2000;62:45-73.
74. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 2006;350:385-391.
75. Sun K, Wang Q, Huang XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol Sin 2006; 27:715-723.
76. Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM, et al. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L891-901.
77. Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, Huxlin KR, et al. Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol 2009;41:722-730.
78. Lin Q, Fang LP, Zhou WW, Liu XM. Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts. Exp Lung Res 2010;36:120-128.
79. Tan X, Dagher H, Hutton CA, Bourke JE. Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res 2010;11:21.
80. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004;53:200-208.
81. Maeda A, Horikoshi S, Gohda T, Tsuge T, Maeda K, Tomino Y. Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)gamma. Cell Biol Int 2005;29:422-428.
82. Zou R, Xu G, Liu XC, Han M, Jiang JJ, Huang Q, et al. PPARgamma agonists inhibit TGF-beta-PKA signaling in glomerulosclerosis. Acta Pharmacol Sin 2010;31:43-50.
83. Wang W, Liu F, Chen N. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts. Mediators Inflamm 2007;2007:62641.
84. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009;89:47-58.
85. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004;50:1305-1318.
86. Zhang GY, Yi CG, Li X, Ma B, Li ZJ, Chen XL, et al. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. Br J Dermatol 2009;160:762-770.
87. van Westerloo DJ, Florquin S, de Boer AM, Daalhuisen J, de Vos AF, Bruno MJ, et al. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol 2005;166:721-728.
88. Peng Y, Liu H, Liu F, Liu Y, Li J, Chen X. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells. Nephrology (Carlton) 2006;11:516-523.
89. Lee HM, Kang HJ, Park HH, Hong SC, Kim JK, Cho JH. Effect of peroxisome proliferator-activated receptor gamma agonists on myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts. Ann Otol Rhinol Laryngol 2009;118:721-727.
90. Fu M, Zhang J, Zhu X, Myles DE, Willson TM, Liu X, et al. Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem 2001;276:45888-45894.
91. Zheng S, Chen A. Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007;292:G113-123.
92. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002;14:681-685.
93. Liu G, Ding W, Neiman J, Mulder KM. Requirement of Smad3 and CREB-1 in mediating transforming growth factor-beta (TGF beta) induction of TGF beta 3 secretion. J Biol Chem 2006;281:29479-29490.
94. Wolf G. Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab 1998;24:174-180.
95. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin IIinduced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993;92:1366-1372.
96. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
97. Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, et al. Klotho inhibits transforming growth factor-beta1 (TGFbeta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011;286:8655-8665.
98. Zhang H, Li Y, Fan Y, Wu J, Zhao B, Guan Y, et al. Klotho is a target gene of PPAR-gamma. Kidney Int 2008;74:732-739.
99. Yamagishi T, Saito Y, Nakamura T, Takeda S, Kanai H, Sumino H, et al. Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. Hypertens Res 2001;24:705-709.
100. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002;109:787-796.
101. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004;63:423-432.
102. Wenzel S, Taimor G, Piper HM, Schlüter KD. Redoxsensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGFbeta expression in adult ventricular cardiomyocytes. FASEB J 2001;15:2291-2293.
103. Hao GH, Niu XL, Gao DF, Wei J, Wang NP. Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol 2008;153: 1409-1419.
104. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002;118:211-215.
105. Mori Y, Chen SJ, Varga J. Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-beta. Exp Cell Res 2000;258:374-383.
106. Wei J, Ghosh AK, Sargent JL, Komura K, Wu M, Huang QQ, et al. PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010;5:e13778.
107. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 2000;97:4844-4849.
108. Prasad R, Giri S, Singh AK, Singh I. 15-deoxy-delta12,14-prostaglandin J2 attenuates endothelial-monocyte interaction: implication for inflammatory diseases. J Inflamm (Lond) 2008;5:14.
109. Kahn BB, McGraw TE. Rosiglitazone, PPARγ, and type 2 diabetes. N Engl J Med 2010;363:2667-2669.